Previous 10 | Next 10 |
Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...
Eurofins Scientific S.E. (ERFSF) is expected to report for Q4 2023 Biodesix Inc. (BDSX) is expected to report $-0.1 for Q4 2023 Tapinator Inc (TAPM) is expected to report for quarter end 2023-12-31 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.31 for Q4 2023 Galapag...
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Ch...
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present a...
2023-12-16 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KALA BIO Inc. (KALA) is expected to report $-2.15 for Q3 2023
2023-11-13 14:34:07 ET More on Kala Pharmaceuticals Seeking Alpha’s Quant Rating on Kala Pharmaceuticals Historical earnings data for Kala Pharmaceuticals Financial information for Kala Pharmaceuticals For further details see: Kala Pharmaceuticals ...
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ...
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq L...
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present ...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- ...
2024-04-12 19:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-03 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KALA on April 3, 2024 06:43AM ET. The previous analyst recommendation was Buy. KALA was trading at $7.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...